iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin Clears USFDA Warning Letter for Goa and Pithampur Facilities

28 Jul 2023 , 10:13 AM

Lupin Limited (Lupin), a global pharmaceutical major, received correspondence from the US FDA confirming the resolution of concerns raised in the Warning Letter for its facilities in Goa and Pithampur Unit-2, Indore.

The US FDA’s evaluation of the corrective actions taken by Lupin resulted in the satisfactory resolution of the issues mentioned in the Warning Letter, which was initially issued on November 6, 2017.

Nilesh Gupta, Managing Director of Lupin, expressed his satisfaction with the positive feedback and reiterated the company’s commitment to adhering to good manufacturing practices and maintaining global quality standards for their products.

Addressing the concerns raised by regulatory authorities is crucial for pharmaceutical manufacturers to ensure the quality and safety of their products for public health.

Lupin’s proactive approach to resolving the issues highlighted in the Warning Letter showcases the company’s dedication to upholding its reputation and building consumer trust.

This milestone reaffirms Lupin’s determination to meet stringent regulatory requirements and strengthens its position in the global pharmaceutical market. The positive feedback from the US FDA marks a significant achievement for Lupin, enhancing its pursuit of excellence in providing healthcare solutions.
For feedback and suggestions, write to us at editorial@iifl.com

Lupin Clears USFDA Warning Letter for Goa and Pithampur Facilities

Related Tags

  • Lupin
  • Pharma
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.